LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global standard for gene delivery systems, ISO 16921 ...
Accelerate CGT developement with strategic viral vector manufacturing and CDMO partnerships that balance quality, cost, and ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results